**Author's response to reviews**

**Title:** Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study

**Authors:**

Teresa Rolle (teresa.rolle@unito.it)

Roberta Spinetta (spinetta.roberta@gmail.com)

Raffaele Nuzzi (prof.nuzzi_raffaele@hotmail.it)

**Version: 1 Date: 06 Jun 2017**

**Author’s response to reviews:**

Reviewer(s)' Comments to Authors:

Marcelo Ayala, M.D., PhD, Associate Professor (Reviewer 1)

Comments to the Author

1) Thanks for the opportunity to revise your manuscript. The information presented is useful and important.

Minor points: the abstract and the introduction must be shortened

Answer : Dear Professor Ayala, thank you for your comments. As suggested, we have shortened both the abstract and the introduction.

2) Please add in the methods if patients in the groups were using any kind of eye-drops like natural tears.

Answer : we have outlined that the use of other ocular medications including artificial tear therapy was considered an exclusion criteria both for the control (Methods section, page 5, line 101) and the therapy groups (Methods section, page 5, line 108), thank you.

3) The discussion part must be re-organized, it's difficult to follow. There are just lots of small sentences. Please put these together as paragraph.

Answer The discussion has been restructured and now it's more systematic.

4) Finally, the use of English should be improved, please let a native English speaking editor revise the manuscript.
Maurizio Digiuni, M.D, (Reviewer 2)

Comments to the Authors

1) In the title and conclusion of the paper you write about safety and tolerability without define these two parameters. So, please define safety and tolerability in the methods.

Answer: Dear Doctor Digiuni, thank you for your comments. We have added the definitions of safety and tolerability in the methods (Methods section, page 4, lines 80 and 83-88), thank you.

2) Please specify in methods how many times per day PF-Timolol was administered. QD vs BID?

Answer: PF-Timolol was administered QD, we have pointed out as suggested (Methods section, page 5, line 97).